Expert commentary: The DUAL VIII trial
Sanjay Kalra discusses the implications of the DUAL VIII trial, which looked at the effect of IDegLira versus glargine on the time to treatment intensification in people with type 2 diabetes (2:39).
News story | IDegLira delays need for treatment intensification over glargine
News story | Support for add-on IDegLira in SGLT2 inhibitor-treated type 2 diabetes
News story | Real-world data confirm benefits of IDegLira